WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during t ...

The acquisition is non-dilutive for shareholders and expected to generate over $30 million in annual premiums, with $8 million in annual revenues over the next twelve months after closing, and a 25% net income margin on a standalone basisNEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Roadzen Inc. (Nasdaq: RDZN), a global leader in AI at the intersection of insurance and mobility, today announced that it has signed a definitive agreement to acquire majority control of a commercial auto insurance broker and mana ...

CELEBRATION, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra’s executive leadership team will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston, MA on Wednesday, November 12, 2025, at 11:30 a.m. ET. Additionally, management will be available for one-on-one meetin ...

BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 1 ...

Q3-2025 Net Income of $6.7 million, EBITDA1 of $18.7 million and Free Cash Flow to Equity1 of $11.1 millionFull Debt Repayment Achieved in October 2025Quarterly dividend Increased by 33%Quarterly Dividend of Cdn$0.04 Declared VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce a strong financial performance for the three months ended September 30, 2025 (“Q3-2025”) and the full repayment of corporat ...

Vancouver, BC, Oct. 29, 2025 (GLOBE NEWSWIRE) -- First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (“First American Uranium”, or the “Company”) is pleased to announce the successful completion of a site visit to its Seigneurie Property, located in the Regional County Municipality of La Haute-Côte-Nord in Quebec’s Grenville Proterozoic Province. The visit was conducted on October 22, 2025, by Murray Nye, Chief Executive Officer and Clyde McMillan, Technical Advisor. Purpose and Key Findings Th ...

Core Insights - ProKidney Corp. is a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD) [1][2] - The company will participate in two upcoming healthcare conferences in November 2025, including the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference [1] Company Overview - ProKidney was founded in 2015 after a decade of research and is a pioneer in the treatment of CKD through innovations in cellular therapy [2] - The lead product candidate, rilparencel (REACT), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation [2] - Rilparencel is currently being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes [2]

JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the sec ...

Core Insights - Virtu Financial, Inc. reported a strong financial performance for the third quarter of 2025, with total revenues increasing by 16.7% to $824.8 million compared to $706.8 million in the same period of 2024 [4][11] - The company declared a quarterly cash dividend of $0.24 per share, payable on December 15, 2025 [3] Financial Results - Total revenues for Q3 2025 reached $824.8 million, a 16.7% increase from $706.8 million in Q3 2024 [4] - Trading income, net, rose by 19.2% to $529.1 million compared to $444.0 million in the prior year [4] - Net income for the quarter was $149.1 million, up from $119.0 million in Q3 2024 [4][11] - Basic and diluted earnings per share were $0.86, compared to $0.65 and $0.64 for the same period in 2024 [5] Adjusted Financial Metrics - Adjusted Net Trading Income increased by 20.4% to $467.0 million for Q3 2025, compared to $388.0 million in Q3 2024 [6] - Adjusted EBITDA rose by 24.7% to $267.8 million, compared to $214.8 million in the same period last year [6] - Normalized Adjusted Net Income increased by 26.1% to $166.5 million, compared to $132.1 million in Q3 2024 [6] Operating Segments - The company operates in two segments: Market Making and Execution Services [8][9] - Market Making segment includes trading across various asset classes, while Execution Services focuses on agency-based trading and technology services [8][9] Share Repurchase Program - Since the inception of the share repurchase program in November 2020, the company has repurchased approximately 53.8 million shares for about $1.417 billion [15] - The remaining capacity for future purchases under the program is approximately $302.8 million [15] Financial Condition - As of September 30, 2025, Virtu had $755.4 million in cash and cash equivalents, with total long-term debt of $2.0687 billion [14]

Third quarter revenue of $768 million, up 5.9%, and up 5.5% on an organic constant currency (OCC) basis.Net income of $226 million, up 2.5% as strong operating performance were partially offset by higher net interest expense in the current year and investment gain in the prior year.Adjusted EBITDA, a non-GAAP measure, of $429 million, up 7.2%, and up 8.8% on an OCC basis.Diluted GAAP earnings per share of $1.61, up 4.5%.Diluted adjusted EPS, a non-GAAP measure, of $1.72, up 3.0%.Pending AccuLynx acquisition ...